Welcome to our dedicated page for APIMEDS PHARMACEUTICALS US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) provides access to the company’s regulatory disclosures as an Exchange Act registrant with common stock listed on the NYSE American. These filings document key aspects of Apimeds’ evolution as a clinical-stage biopharmaceutical company focused on non-opioid, biologic-based pain therapies and its merger with MindWave Innovations Inc., an institutional Digital Asset Treasury solutions provider.
Among the most informative documents are the company’s current reports on Form 8-K, which describe material events such as the entry into an Agreement and Plan of Merger with MindWave Innovations Inc., Apimeds Merger Sub, Inc., and Lokahi Therapeutics, Inc.; the structure of the merger consideration, including common and preferred stock; and the resulting ownership percentages. Other 8-K filings detail amendments to bylaws to allow shareholder action by written consent, changes to executive employment agreements, and departures or removals of directors, along with the composition of the remaining board.
Filings also address capital structure and financing arrangements, including a Securities Purchase Agreement for senior convertible notes, amendments to that agreement, and a certificate of designation for Series A Convertible Preferred Stock. An amended Form 8-K (8-K/A) explains corrections to the merger agreement and to the number of preferred shares designated, illustrating how Apimeds uses SEC filings to clarify and update previously reported terms.
Investors reviewing APUS filings can trace the company’s initial public offering on the NYSE American, its status as an emerging growth company, and subsequent PIPE financing associated with the MindWave merger, as described across registration statements and current reports. The filings also reference the preparation of an Information Statement under Section 14(c) of the Exchange Act to describe the merger, related stockholder approvals, reverse stock split, and equity incentive plan changes.
On Stock Titan, these SEC documents are supplemented by AI-powered summaries that highlight the main points of lengthy filings, such as 8-Ks and related exhibits. Users can quickly understand how each filing relates to Apimeds’ Apitox development program, its non-opioid pain-management focus, its integration of digital-asset treasury capabilities, and its governance and capital structure decisions, without reading every page in full.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a Form 4 for a director showing a grant of a stock option for 10,000 shares at an exercise price of $2.67 on 11/11/2025.
The option expires on 11/11/2035 and vests quarterly beginning October 1, 2025, becoming fully vested after three years. It is not exercisable until stockholder approval of an amendment to the incentive plan to increase available shares. The option vests in full upon a Change in Control.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a routine insider equity grant. A director received a stock option covering 10,000 shares on 11/11/2025 with an exercise price of $2.67 and an expiration date of 11/11/2035.
The option vests in quarterly installments beginning October 1, 2025, becoming fully vested after three years. It is not exercisable until stockholder approval is obtained for an amendment to the company’s incentive plan to increase shares available under the plan. The award vests in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) disclosed a director stock option grant. On 11/11/2025, the reporting person acquired a stock option for 10,000 shares at an exercise price of $2.67, with an expiration date of 11/11/2035. The option was received for $0 and is held as Direct (D) ownership.
The award vests in quarterly installments beginning October 1, 2025 and will be fully vested after three years, subject to continued service on each vesting date. It is not exercisable until stockholder approval is obtained for an amendment to the Company’s incentive plan to increase available shares. The option will vest in full upon a Change in Control as defined in the plan.
Apimeds Pharmaceuticals US, Inc. (APUS) reported Q3 2025 results. The company recorded a net loss of $1,781,255 for the quarter and $4,845,845 for the nine months ended September 30, 2025. Operating expenses rose as the company ramped research and development and expanded general and administrative activity.
Cash was $6,986,617 as of September 30, 2025. The company completed an IPO on May 12, 2025, issuing 3,375,000 shares at $4.00 per share and generating net proceeds of $11.9 million. Management states available cash, together with IPO proceeds, is sufficient to fund the current operating plan for at least the next twelve months from the financial statement issuance date.
R&D expenses were $619,693 in Q3, driven mainly by clinical trial costs, while G&A totaled $1,224,546. Shares outstanding were 12,575,983 as of September 30, 2025. Subsequent to quarter-end, the company paid a non-refundable fee of $700,000 to waive certain underwriting rights and approved 510,500 stock options at an exercise price of $1.92. Disclosure controls and procedures were deemed not effective due to material weaknesses in internal control over financial reporting.
Apimeds Pharmaceuticals US, Inc. (APUS) director reported receiving a stock option grant. The option covers 3,000 shares of common stock at an exercise price of $1.92 per share, granted on 10/15/2025 and expiring on 10/15/2035.
The award vests in quarterly installments beginning October 1, 2025 and becomes fully vested after three years, subject to continued service. It is not exercisable until stockholder approval is obtained to amend the incentive plan to increase available shares. The option vests in full upon a Change in Control as defined in the plan.
Following the transaction, the reporting person beneficially owns 3,000 derivative securities on a direct basis.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director stock option grant on a Form 4. The award covers 3,000 stock options at an exercise price of $1.92, granted on October 15, 2025, and expiring on October 15, 2035. Vesting occurs quarterly beginning October 1, 2025 and completes after three years, contingent on continued service. The option is not exercisable until stockholders approve an amendment to increase shares under the incentive plan; it vests in full upon a Change in Control.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s stock option grant on a Form 4. The award covers 3,000 stock options at an exercise price of $1.92, granted on 10/15/2025 and expiring on 10/15/2035.
The options vest in quarterly installments beginning October 1, 2025, becoming fully vested after three years, subject to continued service on each vesting date. The options are not exercisable until stockholder approval is obtained to amend the company’s incentive plan to increase shares available. The award will vest in full upon a Change in Control as defined in the plan. Following the transaction, the reporting person holds 3,000 derivative securities with direct ownership.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s grant of stock options. The filing shows 3,000 options at an exercise price of $1.92 per share on 10/15/2025, owned directly.
The options vest in quarterly installments beginning October 1, 2025 and become fully vested after three years. They are not exercisable until stockholder approval of an amendment to increase shares under the company’s incentive plan. The award accelerates to full vesting upon a Change in Control and expires on 10/15/2035.
Apimeds Pharmaceuticals US, Inc. (APUS) insider filing: A director and officer (Chairman and CMO) reported a grant of 3,000 stock options on 10/15/2025 at an exercise price of $1.92 per share. The options expire on 10/15/2035 and vest in quarterly installments beginning October 1, 2025, becoming fully vested after three years, contingent on continued service. The options are not exercisable until stockholders approve an amendment to increase shares under the incentive plan. Following the grant, 3,000 derivative securities are beneficially owned directly.
Apimeds Pharmaceuticals US, Inc. (APUS) reported a director’s grant of stock options. The filing shows 3,000 stock options acquired on 10/15/2025 at an exercise price of $1.92 per share, expiring on 10/15/2035. Following the transaction, the reporting person beneficially owns 3,000 derivative securities, held directly.
The options vest in quarterly installments beginning October 1, 2025 and become fully vested after three years, with full vesting upon a Change in Control as defined in the plan. The options are not exercisable until stockholder approval is obtained to amend the incentive plan to increase available shares.